Eric M. Dube Sells 10,736 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CEO Eric M. Dube sold 10,736 shares of Travere Therapeutics stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $19.46, for a total transaction of $208,922.56. Following the sale, the chief executive officer now owns 351,239 shares in the company, valued at approximately $6,835,110.94. This trade represents a 2.97 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Travere Therapeutics Price Performance

TVTX stock traded up $1.35 during midday trading on Thursday, reaching $20.81. The company had a trading volume of 2,031,403 shares, compared to its average volume of 1,331,242. The firm has a 50-day moving average price of $18.28 and a 200-day moving average price of $14.79. The company has a market capitalization of $1.62 billion, a P/E ratio of -4.57 and a beta of 0.70. Travere Therapeutics, Inc. has a 1 year low of $5.12 and a 1 year high of $20.89. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.01. The business had revenue of $62.90 million during the quarter, compared to analyst estimates of $60.87 million. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. Travere Therapeutics’s quarterly revenue was up 69.6% compared to the same quarter last year. During the same period last year, the business posted ($1.17) earnings per share. On average, research analysts anticipate that Travere Therapeutics, Inc. will post -3.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Guggenheim upped their price objective on Travere Therapeutics from $23.00 to $41.00 and gave the company a “buy” rating in a research note on Wednesday, October 9th. Cantor Fitzgerald started coverage on Travere Therapeutics in a report on Friday, January 10th. They set an “overweight” rating for the company. Piper Sandler upped their target price on shares of Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a report on Thursday, November 14th. Wedbush boosted their price objective on Travere Therapeutics from $17.00 to $25.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 9th. Finally, Citigroup lowered their price target on shares of Travere Therapeutics from $23.00 to $19.00 and set a “buy” rating for the company in a research report on Friday, September 27th. One analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, Travere Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of TVTX. R Squared Ltd purchased a new stake in Travere Therapeutics during the fourth quarter valued at $53,000. CWM LLC lifted its position in shares of Travere Therapeutics by 158.5% in the 3rd quarter. CWM LLC now owns 4,999 shares of the company’s stock worth $70,000 after purchasing an additional 3,065 shares during the period. DRW Securities LLC bought a new stake in Travere Therapeutics during the second quarter valued at about $95,000. Quarry LP acquired a new position in shares of Travere Therapeutics during the third quarter worth $105,000. Finally, Forefront Analytics LLC increased its holdings in shares of Travere Therapeutics by 10.2% during the second quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock valued at $109,000 after acquiring an additional 1,237 shares in the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.